CoChat
Sign Up
Cited by 67Lipoproteins and Cardiovascular HealthLipid metabolism and disordersDiabetes, Cardiovascular Risks, and Lipoproteins

Hypertriglyceridemia in statin-treated US adults: the National Health and Nutrition Examination Survey

Fan, Wenjun, Philip, Sephy, Granowitz, Craig, Toth, Peter P., Wong, Nathan D.·2019·Journal of Clinical Lipidology
DOI 10.1016/j.jacl.2018.11.008
Open this paper in CoChat — free account

Abstract

Background Statin therapy remains the primary treatment for mixed dyslipidemia, even with moderate triglyceride (TG) elevations.Objective We examined the prevalence of elevated TG levels in adults with and without statin use and the associated 10-year predicted atherosclerotic cardiovascular disease (ASCVD) risk.Methods We studied 9593 US adults aged ≥20 years (219.9 million projected) in the US National Health and Nutrition Examination Surveys, 2007 to 2014. We determined the proportions of TG categories (<150, 150-199, 200-499, and ≥500 mg/dL) according to statin use, as well as the 10-year estimated ASCVD risk and number of events.Results Among those not taking statin therapy, the prevalence of TG < 150, 150 to 199, and ≥200 mg/dL was 75.3%, 12.8%, and 11.9%; among statin users, these proportions were 68.4%, 16.2%, and 15.4%, respectively. Among persons with low-density lipoprotein cholesterol <100 mg/dL (or <70 mg/dL in those with ASCVD), despite statin use, 27.7% had TG ≥ 150 mg/dL. The odds of TG ≥ 150 mg/dL in statin users was associated with greater age, higher body mass index, lower high-density lipoprotein cholesterol, higher low-density lipoprotein cholesterol, and diabetes. Estimated mean 10-year ASCVD risk from TG < 150 to ≥500 mg/dL, ranged from 11.3% to 19.1% in statin users and 6.0% to 15.6% in nonusers, with an overall 3.4 million ASCVD events expected in the next 10 years.Conclusions One-fourth of US adults overall, including nearly one-third of those on statin therapy, have suboptimal TG levels. More than 3 million ASCVD events are expected to occur over the next decade in those with TG ≥ 150 mg/dL, with approximately 1 million events expected in statin users.

Integrity signals

Registry

Crossref · 10.1016/j.jacl.2018.11.008

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In the United States, >15 million patients with triglycerides ≥135 mg/dL are on statins.

    “In the United States, there are at least 70 million patients with triglycerides ≥135 mg/dL, with >15 million of those on statins, and >7 million of those with LDL-C controlled to <100 mg/dL.”

    From REDUCE-IT USA: Results From the 3146 Patients Randomized in the United States (2020) · cites this paper as [16]

  • In the United States, >7 million patients with triglycerides ≥135 mg/dL have LDL-C controlled to <100 mg/dL.

    “In the United States, there are at least 70 million patients with triglycerides ≥135 mg/dL, with >15 million of those on statins, and >7 million of those with LDL-C controlled to <100 mg/dL.”

    From REDUCE-IT USA: Results From the 3146 Patients Randomized in the United States (2020) · cites this paper as [16]

  • In the United States, there are at least 70 million patients with triglycerides ≥135 mg/dL.

    “In the United States, there are at least 70 million patients with triglycerides ≥135 mg/dL, with >15 million of those on statins, and >7 million of those with LDL-C controlled to <100 mg/dL.”

    From REDUCE-IT USA: Results From the 3146 Patients Randomized in the United States (2020) · cites this paper as [16]

  • It is estimated that almost 5 million US patients fit the REDUCE-IT patient profile.

    “It is estimated that there are almost 5 million US patients who fit the REDUCE-IT patient profile: statin-treated with diabetes mellitus or established cardiovascular disease who are ≥45 years of age with LDL-C <100 mg/dL.16,17”

    From REDUCE-IT USA: Results From the 3146 Patients Randomized in the United States (2020) · cites this paper as [16]

Cites

Flagged first, then by citations

2 of the 24 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Related

Authors
Fan, W., Philip, S., Granowitz, C., Toth, P. P., & Wong, N. D.
Affiliations
  • University of California, Irvine (US)
  • Amarin (United States) (US)
  • Johns Hopkins University (US)
Corresponding author
Wong, Nathan D.
ORCID
Venue
Journal of Clinical Lipidology
Publisher
Elsevier BV
Published
2019-01
Volume
13
Issue
1
Pages
100-108
ISSN
  • 1876-4789 (ISSN-L)
  • 1933-2874
DOI
10.1016/j.jacl.2018.11.008
OpenAlex
W2902364078
Cited by
67
References
24
Citations by year
2026: 4 · 2025: 3 · 2024: 6 · 2023: 12 · 2022: 10 · 2021: 4 · 2020: 16 · 2019: 12
FWCI
8.37
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Journal of clinical lipidology (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Amarin Corporation
  • University of California, Irvine
Topics
  • Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
hypertriglyceridemia, statin therapy, triglyceride levels, atherosclerotic cardiovascular disease risk, mixed dyslipidemia, prevalence, LDL cholesterol, HDL cholesterol, diabetes mellitus, body mass index
MeSH terms
Adult, Drug Utilization, Female, Humans, Male, Middle Aged, Nutrition Surveys, Risk, Triglycerides, United States, Hypertriglyceridemia, Comorbidity, Prevalence, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Atherosclerosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review